Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) serves as a notification of the submission of its Annual Report 2009 on Form 20-F to the SEC. The filing date is March 1, 2010, and the report covers the fiscal year ended December 31, 2009.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the referenced Annual Report 2009 on Form 20-F, which includes audited financial statements.
Material Changes
The filing text does not provide data regarding material changes versus the prior comparable period. Investors must refer to the full Form 20-F for comparative financial analysis.
Guidance, Outlook, and Risks
The filing includes a cautionary statement regarding forward-looking statements under the US Private Securities Litigation Reform Act of 1995. It notes that actual results may differ materially from projections due to risks and uncertainties. Specific risk factors are described in the 'Business review' section of the Annual Report 2009 on Form 20-F. No specific guidance or outlook figures are provided in this summary document.
Important Facts for Investors to Verify
- The filing is a procedural notice confirming the submission of the 2009 Annual Report (Form 20-F) on March 1, 2010.
- Audited financial statements for the year ended December 31, 2009, are available in the referenced Form 20-F.
- Hard copies of the Annual Report and Notice of Annual General Meeting were expected to be available on or about March 16, 2010.
- Shareholders can request free hard copies of audited financial statements via Equiniti (UK), BNY Mellon Shareowner Services (US), or the GSK Response Center (US).
- Forward-looking statements in the report are subject to risks detailed in the full Form 20-F.